Summary: Evaluated atorvastatin versus placebo given to diabetic patients for primary prevention of major adverse cardiac events (MACE). Major benefit was seen with atorvastatin including all-cause mortality reduction, acute coronary syndrome reduction, stroke reduction, and coronary revascularization reduction. About 2/3 of patients in this trial had LDL levels at goal prior to starting atorvastatin. All diabetics are now recommended to be on statin therapy regardless of their LDL level.

Original Publication:

Lancet. 2004 Aug 21-27;364(9435):685-96.

Eponym: Collaborative AtoRvastatin Diabetes Study